The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) is a huge mover today! About 500,832 shares traded hands or 85.94% up from the average. Abeona Therapeutics Inc (NASDAQ:ABEO) has risen 167.11% since March 2, 2016 and is uptrending. It has outperformed by 158.85% the S&P500.
The move comes after 7 months positive chart setup for the $223.90 million company. It was reported on Oct, 5 by Barchart.com. We have $9.70 PT which if reached, will make NASDAQ:ABEO worth $94.04 million more.
Analysts await Abeona Therapeutics Inc (NASDAQ:ABEO) to report earnings on November, 15. They expect $-0.13 earnings per share, up 31.58% or $0.06 from last year’s $-0.19 per share. After $-0.20 actual earnings per share reported by Abeona Therapeutics Inc for the previous quarter, Wall Street now forecasts -35.00% EPS growth.
Abeona Therapeutics Inc (NASDAQ:ABEO) Ratings Coverage
Out of 3 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Abeona Therapeutics has been the topic of 4 analyst reports since December 16, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Maxim Group given on Thursday, September 29. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) earned “Buy” rating by Cantor Fitzgerald on Thursday, September 8. Maxim Group initiated the shares of ABEO in a report on Wednesday, December 16 with “Buy” rating. Rodman & Renshaw reinitiated the shares of ABEO in a report on Wednesday, April 20 with “Buy” rating.
According to Zacks Investment Research, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.”
More recent Abeona Therapeutics Inc (NASDAQ:ABEO) news were published by: Streetinsider.com which released: “FBR Still Positive on Abeona Therapeutics (ABEO) Following DSMB Review of ABO-102” on October 05, 2016. Also Marketwatch.com published the news titled: “/quotes/zigman/3870025/realtime” on June 22, 2015. Benzinga.com‘s news article titled: “263% Upside Seen In Abeona Therapeutics” with publication date: September 21, 2016 was also an interesting one.
ABEO Company Profile
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., incorporated on June 22, 1989, is focused on developing and delivering gene therapy and plasma products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV) gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Firm is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease (COPD) using its salt diafiltration (SDF) ethanol-free process. The Company’s product pipeline also consists of MuGard and ProdiGard.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.